Your institution may have access to this item. Find your institution then sign in to continue.
Title
Myeloablative <sup>131</sup>I-Tositumomab Radioimmunotherapy in Treating Non-Hodgkin's Lymphoma: Comparison of Dosimetry Based on Whole-Body Retention and Dose to Critical Organ Receiving the Highest Dose.